Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Prevalence of hyperkalemia among hemodialysis patients in Egypt.

Khedr E, Abdelwhab S, El-Sharkawy M, Ali M, El Said K.

Ren Fail. 2009;31(10):891-8. doi: 10.3109/08860220903216097. Erratum in: Ren Fail. 2010 Jan;32(1):151. El-Sharkay, Magdy [corrected to El-Sharkawy, Magdy].

PMID:
20030523
2.
3.

Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.

Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD.

Am J Med. 2002 Feb 1;112(2):110-4.

PMID:
11835948
4.

The effect of use of dates on serum potassium in nondiabetic hemodialysis patients.

Siddiqi N, El Shahat O, Bokhari E, Roujouleh H, Hamid MH, Sheikh I, El-Sayed H, Saleh A, Seddik A.

Saudi J Kidney Dis Transpl. 2009 Nov;20(6):1018-22.

5.

Analysis of factors causing hyperkalemia.

Takaichi K, Takemoto F, Ubara Y, Mori Y.

Intern Med. 2007;46(12):823-9. Epub 2007 Jun 15.

6.

The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function.

Garthwaite E, Bhandari S.

Artif Organs. 2009 Aug;33(8):641-7. doi: 10.1111/j.1525-1594.2009.00790.x. Epub 2009 Jun 28.

PMID:
19624582
7.

Glucose-charged dialysate for children on hemodialysis: acute dialytic changes.

Fischbach M, Terzic J, Bitoun Cohen C, Cousandier E, Hamel G, Battouche D, Geisert J.

Pediatr Nephrol. 1998 Jan;12(1):60-2.

PMID:
9502570
9.

Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.

Lin HH, Yang YF, Chang JK, Ting IW, Kuo HL, Wang IK, Huang CC.

Ren Fail. 2009;31(10):942-5. doi: 10.3109/08860220903216147.

PMID:
20030530
10.

[Hyperkalemia during prolonged use of angiotensin II-converting enzyme inhibitors in end-stage renal insufficiency].

Mooser V, Fellay G, Regamey C.

Schweiz Med Wochenschr. 1992 Dec 12;122(50):1927-9. French.

PMID:
1465596
11.
12.

Electrocardiographic manifestations of hyperkalemia in hemodialysis patients.

Nemati E, Taheri S.

Saudi J Kidney Dis Transpl. 2010 May;21(3):471-7.

13.

[Hyperkalemia in hypertensive patients undergoing regular hemodialysis during enalapril and fosinopril therapy].

Dimković N, Djordjević T, Popović J, Dimković S, Tirmenstajn-Janković B, Zivanović M, Bobanović-Hasković J.

Srp Arh Celok Lek. 2006 Jan-Feb;134(1-2):44-8. Serbian.

14.

Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure.

Blumberg A, Weidmann P, Shaw S, Gnädinger M.

Am J Med. 1988 Oct;85(4):507-12.

PMID:
3052050
15.

Ramipril and risk of hyperkalemia in chronic hemodialysis patients.

Krajina-Andricević M, Zibar L, Juras K, Goll-Barić S, Barbić J.

Coll Antropol. 2011 Jun;35(2):537-42.

PMID:
21755729
16.

No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.

Han SW, Won YW, Yi JH, Kim HJ.

Nephrol Dial Transplant. 2007 Apr;22(4):1150-5. Epub 2007 Jan 25.

PMID:
17255126
17.

Prevalence of hyperkalemia in adult patients taking spironolactone and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

Surabenjawong U, Thunpiphat N, Chatsiricharoenkul S, Monsomboon A.

J Med Assoc Thai. 2013 Aug;96(8):905-10.

PMID:
23991595
18.

Management of hyperkalemia in dialysis patients.

Putcha N, Allon M.

Semin Dial. 2007 Sep-Oct;20(5):431-9. Review.

PMID:
17897250
19.

A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.

Kaisar MO, Wiggins KJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Mudge DW, Bofinger A, Petrie JJ, Johnson DW.

Am J Kidney Dis. 2006 May;47(5):809-14.

PMID:
16632019
20.

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D.

J Card Fail. 2004 Aug;10(4):297-303.

PMID:
15309695

Supplemental Content

Support Center